Rathi N, Anderson N, Greenberg S, Vagher J, Agarwal N, Hahn AW. DNA Damage Repair (DDR) Mutations and the Utility of
High-Risk Genetics Clinics in Metastatic Castration-Refractory Prostate Cancer (mCRPC).
World J Oncol 2018;
9:119-122. [PMID:
30220950 PMCID:
PMC6134990 DOI:
10.14740/wjon1144w]
[Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/14/2018] [Accepted: 08/27/2018] [Indexed: 11/11/2022] Open
Abstract
Germline pathogenic variants (PVs) in DNA-repair genes have garnered increasing attention in metastatic prostate cancer, and more patients are having somatic and germline DNA testing performed. Interpretation of germline DNA testing is a novel challenge for many clinicians, and the results of germline DNA-repair gene testing have significant implications for men with advanced prostate cancer and their children and siblings. Here, we report the case of a man with metastatic castration-refractory prostate cancer and a pathogenic, germline BRCA2 variant. We discuss the significance of his referral to a high-risk genetics clinic and the unique targeted therapy that he responded to.
Collapse